Trial Profile
An Open-Label, Single Ascending Dose Study To Evaluate The Pharmacokinetic Profile, Safety and Tolerability of Orally Administered LYC-30937 in Subjects With Active Ulcerative Colitis
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Dec 2016
Price :
$35
*
At a glance
- Drugs Parimifasor (Primary)
- Indications Ulcerative colitis
- Focus Pharmacokinetics
- Sponsors Lycera
- 13 Dec 2016 Status changed from active, no longer recruiting to completed.
- 10 Jul 2016 New trial record